[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malaria-vivax\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malaria-vivax":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,84,114,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100626050","phase-2-this-is-a-clinical-study-to-assess-whether-the-combination-of-sj733-and-tafenoquine-will-be-a-safe-and-rapidly-acting-anti-malarial-for-the-radical-cure-of-p-vivax-malaria-100626050",false,"NCT07430592","This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","A Phase 2B Trial of the Combination of SJ733 and Tafenoquine for Radical Cure of P. Vivax Malaria in Comparison to Chloroquine-Tafenoquine","SJ733-2002","Inclusion Criteria:\n\n* Body weight between 45 kg and 90 kg inclusive.\n* Presence of mono-infection of P. vivax confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral\u002Frectal\u002Ftympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 40,000 asexual parasite count\u002FµL blood\n* Written informed consent provided by participant, in accordance with local practice. If the participant is unable to write, witnessed consent is permitted according to local ethical considerations.\n* Ability to swallow oral medication.\n* Ability and willingness to participate and to comply with the study requirements.\n* Agreement to hospitalization for at least 72 hours and\u002For until malarial parasites are not detected by microscopy on 2 consecutive occasions.\n* Agreement to come back to the hospital on Days 4, 7, 14, 21, 28, 35, 42, 60, 120, and 180.\n* A female participant meets eligibility in this study if she is non-pregnant, non-lactating and if she is of: non-childbearing potential defined as: post-menopausal (12 months of spontaneous amenorrhea or \\\u003C6 months of spontaneous amenorrhea with serum FSH \\>40 mIU\u002FmL), pre-menopausal and has had a hysterectomy, a bilateral oophorectomy (removal of the ovaries), or a bilateral tubal ligation with medical report verification, negative pregnancy test or, child-bearing potential, with a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 75 days after stopping study treatment:\n\n  i. Use of oral, implantable, or injectable hormonal contraceptive, either combined or progestogen alone, used in conjunction with barrier method (condom or diaphragm).\n\nii. Use of an intrauterine device with a documented failure rate of \\\u003C1% per year.\n\niii. Double barrier method consisting of condom and diaphragm. iv. Male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for that female.\n\nv. Complete abstinence from intercourse throughout the study and for a period of 75 days after stopping study treatment.\n\n* A male participant meets eligibility in this study if he meets one of the following conditions:\n\n  1. is sterile prior to participating in the study.\n  2. agrees to the use of a contraceptive method (such as a condom) through the administration of study treatment and for a period of 75 days after stopping study treatment.\n  3. agrees to complete abstinence from intercourse throughout the study and for a period of 75 days after stopping study treatment.\n\nExclusion Criteria:\n\n* Signs and symptoms of severe\u002Fcomplicated malaria according to the World Health Organization Criteria 2010.\n* Mixed Plasmodium infection or Plasmodium mono-infection with any Plasmodium species other than P. vivax.\n* Severe vomiting, defined as more than three times in the 24 hours prior to the planned first dose of drug, or severe diarrhea defined as 3 or more watery stools per day.\n* Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS\u002FWHO normalized reference values).\n* The presence of a significant medical or psychiatric condition, or any other serious or chronic clinical condition requiring hospitalization, or any other condition that in the opinion of the investigator precludes participation in the study.\n* Female participants must not be lactating or pregnant as demonstrated by a negative serum point-of-care pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing).\n* Employment under the direct supervision of the investigators or study staff.\n* Clinically significant alterations to hematologic or clinical chemistry parameters that in the opinion of the investigator precludes participation in the study, including:\n\n  1. AST\u002FALT \\> 3 x upper limit of normal range (ULN) and total bilirubin is normal.\n  2. AST\u002FALT \\> 2 x ULN and total bilirubin is \\>1 and \\\u003C2 x ULN and conjugated bilirubin is \\> 2x ULN.\n  3. Serum creatinine levels \\> 2 x ULN\n  4. Uncorrected electrolyte abnormalities \\[\\> 3x ULN or LLN\\]\n\n  i. Potassium\\[hypokalemia\\] ii. Magnesium \\[hypomagnesemia\\] e. Hb level \\\u003C 9 g\u002FdL f. Platelet level \\\u003C 50,000\u002Fmm3\n* Clinically significant alterations to cardiac function\n\n  1. Unstable angina with elevated serum cardiac biomarkers, ECG changes, etc.; those with NSTE-ACS, NSTEMI, STEMI, or definite acute coronary syndrome.\n  2. Congestive heart failure\n  3. Recent history of Myocardial Infarction\n  4. QT prolongation (\\>450 milliseconds (ms) in men and 460 ms in women)\n* Participation in a clinical study of another small investigational molecule within 30 days or investigational biologic within 90 days prior to study enrollment or planning to begin such participation during the study.\n* Received any antimalarial treatment (alone or in combination) in the past containing:\n\n  1. Tafenoquine within the previous 4 months\n  2. Piperaquine, mefloquine, naphthoquine or sulphadoxine \u002F pyrimethamine within the previous 5 months\n  3. Amodiaquine or chloroquine within the previous 5 months\n  4. Any artemisinin (artesunate, artemether, arteether or dihydroartemisinin), quinine, halofantrine, lumefantrine and any other anti-malarial treatment or antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 3 months.\n* Known history of hypersensitivity, allergic, or adverse reactions to SJ733, tafenoquine or other 8-aminoquinolines, or chloroquine or other 4-aminoquinolines.\n* Current use of prohibited concomitant medications (Appendix III)\n* Known neuropsychiatric disorders.\n* G6PD deficiency \\\u003C70% normal enzyme activity.\n* Prohibited use of metoclopramide, antibiotics including fluoroquinolones\n* Positive HIV and\u002For Hepatitis B, C test results","ALL","18 Years","76 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.",[28,29,30],"Malaria","Malaria Vivax","Radical Cure",[32,33],"SJ733","SJ733 with Tafenoquine","NOT_YET_RECRUITING","2026-05-22",{"date":37,"type":38},"2026-05-28","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2028-11-20",{"name":44,"class":45},"R. Kiplin Guy","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100587069","phase-3-serological-testing-and-treatment-for-plasmodium-vivax-malaria-a-trial-in-ethiopia-and-madagascar-100587069","NCT06923592","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Cluster-Randomised Trial in Ethiopia and Madagascar","PvSTATEM","Inclusion Criteria:\n\n* Participant will remain in the study area for at least the next month.\n* Participant is older than 12 months\n\nExclusion Criteria:\n\n• Participant is unwilling to participate.","12 Months",{"count":57,"type":22},19200,[59],"PHASE3","The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for a majority of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.\n\nWith current technology, it is not possible to directly measure hypnozoite biomarkers. Rather than directly detecting hypnozoites, our team developed an indirect approach by measuring antibodies induced by the primary blood-stage infection. Antibodies to different blood-stage antigens decay at different rates. Measuring antibodies to a carefully selected panel of P. vivax antigens can aid to identify individuals who have been infected within the previous 9 months (approximately the lifespan of hypnozoites).\n\nA serological test based on selected P. vivax antigens can detect recent exposure and predict future relapses. Coupling this test with a safe and efficacious primaquine treatment regimen, results in a population-based intervention to target the hypnozoite reservoir. This intervention is referred to as Plasmodium vivax Serological Testing and Treatment (PvSeroTAT).\n\nPvSTATEM is a cluster randomised trial in Madagascar and Ethiopia. This study will provide insights into the feasibility, acceptability, and efficacy of the PvSeroTAT approach. In this study, individuals, randomised by clusters, will be tested for the presence of serological markers of a recent P. vivax infection, followed by a targeted drug treatment intervention aimed at killing P. vivax hypnozoites.",[29,62,63,64],"Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum",[66,67,68,53,69,70,71,72],"Plasmodium vivax","Vivax","PvSeroTAT","Primaquine","serology","Cluster randomised trial","G6PD","RECRUITING","2026-03-19",{"date":76,"type":38},"2026-03-24",{"date":78,"type":38},"2025-05-12",{"date":80,"type":22},"2027-04-28",{"name":82,"class":45},"London School of Hygiene and Tropical Medicine",2,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":46},"100606220","phase-1-clinical-trial-to-evaluate-the-safety-and-immunogenicity-of-the-vivaxin-vaccine-for-malaria-caused-by-plasmodium-vivax-100606220","NCT07172724","Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax.\"","\"First-in-human, Phase 1, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax.\"","Vivaxin-001","Inclusion Criteria:\n\n1. Non-pregnant women and men aged between 18 and 59 years;\n2. Willingness to participate in the study and undergo all study procedures, as demonstrated by signing the informed consent form (ICF);\n3. In good general health, as determined by medical examination;\n4. Women of childbearing potential must agree to use an acceptable\\* contraceptive method for at least 30 days prior to the first vaccination and for at least 6 months following administration of the first dose of the investigational product, ensuring at least 3 months after the final vaccine dose have elapsed;\n5. Agreement not to donate blood during the course of study participation.\n\n   * Acceptable contraceptive methods:\n\n     * Barrier methods, including condom or cervical cap;\n     * Surgically sterile partner\u002Fparticipant (including those who have undergone vasectomy, hysterectomy, bilateral oophorectomy, and\u002For tubal ligation) who is the sole sexual partner;\n     * Intrauterine device (with or without hormones);\n     * Hormonal birth control methods (oral, topical, injectable, or implantable);\n     * True sexual abstinence that is consistent with the participant's preferred and usual lifestyle.\n\nNote: Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) or withdrawal (coitus interruptus) will not be considered acceptable methods.\n\nExclusion Criteria:\n\n1. Prior history of malaria infection confirmed by serological testing;\n2. Prior history of malaria vaccination;\n3. Intention to travel to a malaria-endemic area during the study period;\n4. Pregnant or breastfeeding women, or those intending to become pregnant or breastfeed within the first 6 months of the study;\n5. Evidence of clinically active disease, such as but not limited to: neurological, renal, cardiovascular, endocrine, pulmonary, hepatic, hematological, immunological, neoplastic, or infectious diseases;\n6. Use of concomitant medication for control of an underlying medical condition;\n7. Positive serological test for HBV, HCV, or HIV;\n8. Any condition that, in the opinion of the study investigator, could pose a risk to the participant or confound the study results, including clinically stable chronic conditions such as diabetes, hypertension, or neuralgias, among others;\n9. Psychiatric illness or cognitive impairment that, in the opinion of the investigator, may affect the participant's ability to comply with the clinical study schedule;\n10. History of alcohol or substance abuse within 12 months prior to enrollment that resulted in family, medical, or occupational problems;\n11. History of severe allergic reaction or anaphylaxis to any component of the vaccine;\n12. History of asplenia;\n13. Participation in any other investigational clinical trial within 12 months prior to inclusion in this study;\n14. Plans to participate in other clinical trials concurrently with this study;\n15. Use of any immunosuppressive therapy within 3 months prior to enrollment or plans to use such therapy within 3 months after vaccination, including corticosteroids or other immunosuppressive drugs. An immunosuppressive dose of corticosteroid is defined as the equivalent of 20 mg\u002Fday of prednisone for more than one week. Topical or nasal corticosteroids are not considered immunosuppressive;\n16. Use of blood products (including blood or immunoglobulins) within 3 months prior to enrollment in this study, or plans to use them during the study period;\n17. Suspected or confirmed fever (axillary temperature ≥ 37.8 °C) within 72 hours prior to study enrollment. Enrollment should be postponed until the participant has been afebrile for at least 72 hours;\n18. Receipt of any live attenuated or inactivated vaccine within 28 or 14 days, respectively, prior to administration of the investigational product, or plans for immunization within 28 days after enrollment in the study.",true,"59 Years",{"count":95,"type":22},48,[97],"PHASE1","Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection",[29],[101,102,66,103,104],"vaccine","malaria","prevention","malaria vivax","2025-09-08",{"date":107,"type":38},"2025-09-15",{"date":109,"type":22},"2025-09",{"date":111,"type":22},"2027-06",{"name":113,"class":45},"Federal University of Minas Gerais",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100567307","phase-3-an-interventional-study-to-compare-the-efficacy-and-safety-of-tafenoquine-tq-and-primaquine-pq-when-either-are-taken-together-with-chloroquine-cq-for-the-treatment-of-p-vivax-malaria-in-indian-participants-aged-2-years-and-older-100567307","NCT06666491","An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of the Efficacy and. Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for the Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population)","Inclusion Criteria:\n\n1. Males and females \\>=2 years of age and under (\\\u003C) 65 years of age, weighing \\>10 kg.\n2. The participant has a positive malarial smear for P. vivax with a parasite density of \\>100\u002Fmicroliter and \\\u003C100,000\u002Fmicroliter.\n3. The participant has a screening Hb value \\>8 g\u002FdL.\n4. The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.\n5. The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units\u002Fgram (U\u002Fg) Hb for G6PD activity (6.1 U\u002Fg Hb cut-off is applicable for both males and females).\n6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:\n\n   * Is a woman of non-childbearing potential (WONCBP) as defined in\n   * Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n7. A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.\n8. The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent\u002Flegal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.\n\nExclusion Criteria:\n\n1. The participant has severe P. vivax malaria as defined by WHO criteria \\[WHO, 2023\\].\n2. The participant has a mixed malaria infection (identified by a malarial smear).\n3. The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).\n4. The participant has a history of porphyria, psoriasis, or epilepsy.\n5. The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.\n6. The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.\n7. The participant has previously enrolled in this study.\n8. The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.\n9. Participants with a current or past history of serious psychiatric disorders.\n10. The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.\n11. The participant is known to be HIV-infected and\u002For is currently on antiretroviral therapy.\n12. The participant is regularly using drugs with hemolytic potential.\n13. The participant has a QT corrected by Fridericia's formula (QTcF) \\>450 msec, evidence of bradycardia (\\\u003C50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (\\\u003C2.9 millimoles per liter \\[mmol\u002FL\\]) or hyperkalemia (\\>=6.0 mmol\u002FL) at Screening.\n14. The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.\n15. The participant has taken or will likely require during the study the use of:\n\n    1. Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)\n    2. Antacids (restricted to first 3 days whilst receiving CQ)\n    3. Drugs of the biguanide class (i.e., phenformin, metformin, buformin)\n    4. Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)\n    5. Medications that prolong the QTc interval\n16. The participant has liver transaminases (ALT\u002FAST) \\>2 times the upper limit of normal (ULN).","2 Years","64 Years",{"count":124,"type":22},300,[59],"The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.",[128],"Malaria, Vivax","2025-08-06",{"date":131,"type":38},"2025-08-07",{"date":133,"type":38},"2024-11-13",{"date":135,"type":22},"2026-05-25",{"name":137,"class":138},"GlaxoSmithKline","INDUSTRY",4,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":46},"100499810","phase-4-act-vs-cq-with-tafenoquine-for-p-vivax-mono-infection-100499810","NCT05788094","ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?","ACTQ","Inclusion Criteria:\n\n* Patients with P. vivax mono-infection as diagnosed by Rapid Diagnostic Test\n* Fever or history of fever in the previous 7 days\n* Quantitative G6PD activity ≥70% of the population median i.e., ≥6.1U\u002FgHb\n* Age \\> 18 years, Weight \\>35 kg\n* Ability to understand the study instructions and provide informed consent\n* Willing to be followed for 4 months and likely to adhere to the study protocol.\n\nExclusion Criteria:\n\n* Coincident P. falciparum malaria or other infections\n* Pregnancy\n* Lactation\n* Hb \\\u003C 8 g\u002FdL\n* Quantitative G6PD activity \\\u003C70% of the population median i.e., \\\u003C6.1U\u002FgHb\n* Severe malaria (as per WHO guideline)\n* History of allergic or haemolytic response to any of the study drugs",{"count":149,"type":22},606,[151],"PHASE4","In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness. This can happen many times even without a mosquito bite. Only 8-aminoquinoline drugs can kill the liver forms of the malaria parasite. One of these drugs is called primaquine, and it has been used all over the world for a long time. There is now a new formulation of this 8-aminoquinoline drug called tafenoquine that can also treat the malaria in the liver. The main benefit of this drug is that it is a single dose, which makes much convenient for the patients as well as for the malaria control program than conventional 14 days of primaquine. Recent research suggests that ACT (Artemisinin Combination Therapy) may antagonise the efficacy of tafenoquine (Baird et al. 2020 ASTMH Annual Meeting) . This could prevent the use of tafenoquine in areas with chloroquine resistant P. vivax parasites where national malaria programmes recommend ACTs for vivax malaria. Also, currently recommended tafenoquine dose is sub-optimal: 300 mg dose proved significantly inferior to low dose primaquine in a meta-analysis of the phase 3 studies when restricted to the Southeast Asian region (Llanos-Cuentas et al. 2019 NEJM; Watson et al. 2022a Elife). A tafenoquine dose of 450mg is predicted to provide \\>90% of the maximal effect. The objective of this research is to find out whether 450 mg dose of tafenoquine can be combined effectively with ACT providing a short course treatment for P. vivax malaria.",[28,128,154],"Plasmodium Vivax Malaria",[156,157,158,28],"artemisinin combination treatment","tafenoquine","Plasmodium vivax malaria","2025-05-13",{"date":161,"type":38},"2025-05-16",{"date":163,"type":38},"2023-06-26",{"date":165,"type":22},"2026-08-31",{"name":167,"class":45},"Shoklo Malaria Research Unit"]